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Montelukast or Singulair has recently been introduced to treat asthma. Because it is 
apparently free of serious side-effects, the present work aimed to investigate its effects on 
chromosomes of bone marrow cells of mice. The percentage of structural chromosomal 
aberrations was highly elevated due to treatment with Montelukast. The aberrations 
increased successively with increasing the time and the dose of the therapy. Numerical 
chromosomal aberrations were also increased, and interstitial deletions  of certain bands 
were detected in G/T-banded karyotypes of the treated samples. Montelukast  appears to 
have potential genotoxicity in the somatic cells of mice in vivo. 
 






Montelukast or Singulair  is an anti-asthma drug belonging to the leukotriene antagonist 
family. It has been available in the United States since March 1998 and has received 
excellent acceptance by physicians, parents and patients (Kemp 2000).Many studies 
indicate that Montelukast demonstrates both anti-inflammatory and bronchodilatory 
properties (Lee et al. 2005), it exhibits additive effects when given with inhalent  
corticosteroids (Stey 2000). 
The pharmacology, pharmacokinetics, clinical efficacy and adverse effects of 
Montelukast, its therapeutic role as a long-term medication and difficulties associated with 
the management of asthma have been reviewed by many specialists (e.g. Blake 1999; 
Jarvis & Markham 2000). Blake (1999) used all the available published reports of 
controlled clinical trials of Montelukast in adults and children with asthma to reach three 
main points. (1) It may be considered for use as first-line therapy in patients with mild 
persistent asthma, or for additional control in patients treated with inhaled corticosteroids. 
(2) It may be used in aspirin-sensitive asthmatic patients. (3) Chronic treatment with 
Montelukast can provide additional control of symptoms during exercise, but inhaled beta-
2 agonists remain the first-line therapy prophylaxis and treatment. 
The most common adverse effects of Montelukast in pediatric studies were headache, 
asthma, and respiratory tract infection at rates not significantly different from those with 
placebo. Montelukast has been associated with Churg-Strauss syndrome in a very small 
number of adults, described as a rare allergic granulomatous eosinophilic vasculitis 
characterized by late-onset asthma and upper air-ways disease including allergic rhinitis, 
sinusitis and systemic vasculitis (Wechsler et al. 1999; Hemelaers et al. 2006). The lack of 
major adverse effects, the palatability of the oral route  administration and the once-daily 
regimen combine to make Montelukast a generally well-tolerated medication in children 
(Price 2000; Alsarra et al. 2005). 
      Due to the importance of  Montelukast , and because it is free of serious side effects, it 
is desirable to assess its genotoxic effects. Here the bone marrow cells of mice were used 
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as a model system. Chromosomal aberration analysis was used as a  genotoxic endpoint. 
Reports concerning the cytogenetic effects of Montelukast on humans or   animals are not 
available, so the present investigation seems to be the first report dealing with this 
problem. 
 
MATERIALS AND METHODS 
  
Four-weeks old Swiss albino mice (Mus musculus) were used in this study, supplied  by  
Abbasia  Farm of  the  Egyptian Organization for Vaccine and Biological Preparations. 60 
mice were divided into 10 experimental groups each of 6 animals and allowed to 
acclimatize for at least 7 days prior to the study. They were fed with standard laboratory 
chaw and tap water.  
The Montelukast was produced by Global Napi Pharmaceuticals (Egypt) in the form of 
film- coated chewable tablets of 5 and 10 mg. The human therapeutic dose is 5mg/d for 
children and 10 mg/d for adults (Storms et al. 2001). These doses were adjusted for mice 
according to Paget & Barnes (1964). Such that the dose for a 30 mg mouse  =  dose for 
human  x 0.0026. By calculation the adjusted doses become 0.013mg/d and 0.026 mg/d. 
These two doses were given to groups of mice (4 groups of 6 mice per dose). Montelukast 
was dissolved in sterile distilled water just before use. The dissolved drug was 
administered  to the animal via oral  gavage  for 7 consecutive days. 
The mice were sacrificed 1, 2, 3 and 8 days post-treatment (n=6 in each case). In addition, 
another group of mice (6 animals) were administered distilled water as a negative control, 
and a positive control used  mice  receiving a single dose of 5 mg cyclophosphamide, a 
known cytotoxic and clastogenic agent. Metaphase chromosomes were prepared according 
to Rickart et al.    (1989). Some of the prepared slides were stained for 15 minutes in 6 % 
Giemsa in phosphate buffer (pH 6.8). These slides were used for screening chromosomal 
aberrations. The other slides were subjected to the Trypsin-Giemsa banding technique, for 
banding analysis as recommended by   Seabright (1971).    
For each animal 50 metaphases were analyzed for chromosomal aberrations using the light 
microscope at 1000× magnification. Structural chromosomal aberrations, (chromatid and 
chromosomal breaks, chromatid and chromosomal gaps, deletions, fragments, chromatid 
exchanges, centric fusion and pulverization) were scored according to Savage (1975), and 
numerical chromosomal aberrations were also counted.  In addition, mouse chromosomes  
were   individually  identified  through the use of  the Trypsin-Giemsa banding technique. 
Karyotypes were prepared according to the system suggested by Wurster (1972). G-band 
patterns of each mouse in the control and treated groups were analyzed in at least 3 
karyotypes. 
Statistical analysis was carried out according to one-way ANOVA to determine the test of 
significance. A 2-way ANOVA test was used, to test for  significant differences amongst 




Data of the resulting structural chromosomal aberrations (Fig. 1) following administration 
of Montelukast are given in Table I. At the 5 mg/d dose deletions, dicentric chromosomes, 
chromosomal gaps and centric fusion represent the most predominant types of aberrations. 
The highest readings of deletions, chromosomal gaps and centric fusion were recorded 3 
days after treatment, whereas dicentric chromosomes, centric separation and chromatid 
exchanges were highest after 8 days. Breaks, rings and acentric fragments were also noted 
but at lower frequencies than other types of chromosomal damage. At the 10mg/d 
treatment, it is obvious that the most frequent types of aberrations are deletions and centric 
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separations. In addition, several metaphases with more than one sign of chromosomal 
aberrations were repeatedly detected. Chromosomal aberrations were highly elevated due 
to the treatment with Montelukast, starting from 24 h post-treatment and increasing 
successively with time of the therapy to reach a maximum after 8 days. The higher dose 
produced greater  damage. The mean of chromosomal aberrations detected after 24 h of 
treatment with 5 or 10 mg  increased significantly (1-way ANOVA: P<0.001).  
 
Table I: The frequency of structural chromosomal damage after treatment with Montelukast.  
 























1 12 − 3 13 19 8 8 2 − 46 7.66 ± 
4.22 
15.33 
 +ve control  
5 mg/kg Cp 
1 52 39 27 20 42 24 92 39 7 300 50 ± 
2.83 
100 
 1 60 12 15 32 56 38 32 7 10 262 43.67± 
1.21** 
87.33 
5 mg/d MK 2 67 2 26 38 61 61 53 10 5 323 53.83± 
1.94 
107.7 
 3 80 19 6 53 36 47 78 16 34 369 61.50± 
2.45 
123 
 8 75 11 30 80 73 84 60 30 6 449 74.81± 
1.48 
149.4 





2 103 4 42 56 55 64 80 1 7 423 70.50± 
1.87 
141.00
 3 131 2 58 52 73 67 60 12 7 470 78.30 ± 
2.16 
156.70
 8 164 2 57 48 78 82 90 4 9 538 89.60± 
1.86 
179.33
Del. = deletion, Ac.F. = acentric fragment,   Cht.Exch. = chromatid exchange,  C.F. =, centric fusion, 
C.S. = centric separation,  Dic. = dicentric, Chrsal g = Chromosomal gap,  B. = break, R. = ring. 
NB: C.S. is not involved in the calculation. Cp = Cyclophosphamide. 




Using 2-way ANOVA showed that the differences between 5mg and 10 mg doses were 
highly significant, and changes due to time were also highly significant, (Table II). The 
effects of Montelukast therefore occurred in a dose- and  time- dependent manner (Fig. 2). 
The changes  between doses were larger than those due to time. The interaction was highly 
significant also, probably because changes with time had a steeper slope for the lower dose 
(Fig. 2).  
 










Fig. 1: Metaphases prepared from mice treated with Montelukast having a: deletion - b: dicentric 





























Fig. 2: The percentage of structural 
chromosomal aberrations following treatment 
with 5&10mg Montelukast & the accompanied 
controls 




Table II: Two-way ANOVA test to observe significant differences amongst the various Treatment and 
sampling times 
 
Numerical aberrations were shown  in the form of hypodiploidy and polyploidy (Table III, 
Fig. 3). Generally hypodiploidy was elevated throughout the time of the experiment. After 24 
h, the difference was non- significant as calculated by 1-way ANOVA 2-way ANOVA 
showed that the changes due to doses were highly significant (P<0.001) and changes due to 
time were significant (P<0.05). The interaction was found to be non-significant (P>0.5). 
Polyploidy showed its highest scores  24 h post-treatment with the two tested doses of the 
drug (1-way ANOVA), followed by gradual decrease with time (Figs. 4 and 5). A 2-way 
ANOVA, revealed highly significant differences due to concentration of the drug and 
significant differences due to time. The interaction was also significant.  
 
Table III: The frequency of numerical chromosomal aberrations in Mus musculus following treatment with 
Montelukast.  
.  Types of aberrations / 300 cells 
Treatment Time in Hypodiploidy Polyploidy 
 days  Total Mean & % S.D. Total Mean & % S.D. 
−ve control 
(distilled water) 
1 22 3.66 
7.33 
1.86 7 1.16 
2.33 
1.16 




1 21 3.5 
7 
1.37 8 1.3 
2.66 
1.03 
 1 21 3.5 * 
7 
1.04 28 4.66 ** 
9.33 
1.75 
5 mg/d MK 
(Montelukast). 
2 42 4 
14 
2.36 22 3.6 
7.33 
1.86 
 3 53 8.83 
17 
2.92 17 2.83 
5.66 
1.83 
 8 34 5.66 
11 
2.16 11 1.83 
3.66 
1.83 
 1 25 4.16 * 
8.33 
0.15 35 6 ** 
11.66 
1.78 
10 mg/d MK 
(Montelukast) 
2 32 5.33 
10.66 
1.03 21 3.5 
7 
0.83 
 3 36 6 
12 
1.78 15 2.5 
5 
1.87 
 8 23 3.83 
6.77 
1.72 14 2.16 
5 
1.94 
 *   A-one-way ANOVA showed non-significant differences, (F=0.026, 0.365, P > 0.5). 




D f SS Ms F-ratio Prob 
Dose 1 4107.00 4107.00 944.13
8
<<0.001 
Duration 3 4472.083 1490.694 342.68
8
<<0.001 
Interaction 3 212.883 70.944 16.309 <<0.001 
Error 40 174.000 4.350   
Total 47 8965.917    

































Fig. 4: The percentage of hypodiploidy in Mus                     Fig. 5: The percentage of polyploidy in Mus  
musculus cells following treatment                                            musculus cells following treatment with  
5 and  10mg  MK                                                                            5 and  10mg  MK  
 
Due to the high percentage of chromosomal aberrations detected in samples after 8 days of 
the treatment, the cytogenetic analysis of G-banded chromosomes was only carried out in 
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studied (Table IV). Interstitial deletions of certain bands were strictly determined in some 
chromosomes. In samples prepared after 5 mg  therapy, the affected chromosomes were 
numbers 1, 3 and 6 (Fig. 6), whereas numbers 3, 4, 8, 12, 14, 16 and 18 were affected in mice 
treated with 10 mg. (Fig. 7). 
 
Table IV: Data of interstitial deletions recorded in chromosomes of mice 8 days post-treatment with 
Montelukast. 
  Interstitial deletions in chromosome no. 
Treatment Results 1 3 4 6 8 12 14 16 18 
  5 mg/d Total no. 7 6 − 8 m− − − − − 
 % 38.89 33.33 − 44.44 − − − − − 
  10 mg/d Total no. − 7 9 − 3 5 6 6 4 
 % − 38.89 50 − 16.67 27.78 33.33 33.33 22.22 
Number of animals/dose = 6; Number of karyotypes examined/dose =18. 
 
Fig. 6: Diagrammatic representation and partial karyotypes show 
interstitial deletions in chromosomes no, 1, 3 and 6. a: del 
of interband which lies between bands 5 & 6. b: del (1 q6) - 
c: del (3q2.3) - d: del (6q3). 
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Fig. 7: Partial karyotypes and idiograms of normal and abnormal 
chromosomes no.3,4,8,12,14,16 & 18 prepared from samples 
treated with 10 mg MK 8 days post-treatment. 
*Notice, del (3q 4.5.6, 4q5, 8q2, 12q5, 14q1, 16q2.3 and 18q1). 
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DISCUSSION 
 Chromosomal aberration assays are considered to be very sensitive end points for 
recognizing the genotoxic effects induced by chemicals (WHO, 1985). The present data  
showed very significant increases in the frequency of chromosomal damage in mice treated 
with Montelukast at all doses and all durations tested. The use of different sampling durations 
has been considered important (Hayashi & Sofuni 1994), and therefore the present analysis 
was carried out at four different times. Elevation of chromosomal damage was observed after 
only 24 h. This result is consistent with that of Mueller &Young (1998), who proposed that 
most chemicals gave a positive response after 24 h, roughly equivalent to the normal length 
of the cell cycle. In the present work, the percentage of chromosomal aberrations increased 
successively by increasing the duration of the therapy, with the maximum value after 8 days. 
This continuity in the elevation of damage indicated the prolonged action of the drug or its 
metabolites on mice bone- marrow cells. Styles et al. (1994) also demonstrated the prolonged 
action of tamoxifen metabolites on bone-marrow cells of mice. In mice treated with 10 mg/d 
Montelukast, the yield of chromosomal aberrations was very significantly higher than that 
induced by the lower dose, and therefore we conclude that the increase in structural 
chromosomal aberrations is time- and dose-related. Furthermore, the induced abnormalities 
were mainly of the chromatid type, suggesting damage at late S or G2 phase (Sarker et al. 
1993). Sorsa et al. (1992) stated that most chemical clastogens induce only chromatid 
aberrations, because the aberrations result from DNA synthesis on a damaged DNA template 
in the S period of the cell cycle. 
At a dose of 5 mg and after 3 days, the most abundant types of structural 
chromosomal aberrations were stable (deletion and centric fusion), whereas dicentric, centric 
separation and chromatid exchange (unstable types) were the most predominant types after 8 
days. At the 10 mg dose, deletion and centric separation (stable and unstable) were frequently 
observed. These observations suggest the greater potential of higher doses and longer 
duration of the drug. In addition, Montelukast enhanced the formation of numerical 
chromosomal aberrations (hypodiploidy or polyploidy). As recommended by  Hoffmann 
(1996), it is useful to separate the induction of structural chromosomal aberration from the 
induction of numerical chromosomal aberration, because the principle target for the induction 
of the former is DNA, whereas the targets of the latter are often components of mitotic or 
meiotic apparatus such as spindle fibers (Ilies, 2002). Agents that damage polymerization of 
tubulin, the principal protein of spindle fibers, cause hyperdiploidy; the chromosomes 
duplicate normally in interphase, but the chromatids do not separate into the daughter cells 
(Vogel & Motulsky 1997). Agents that damage kinetochores can cause aneuploidy, involving 
the gain or loss of one or a few chromosomes (Kingston 1998). 
In samples prepared from animals treated with 5 mg, interstitial deletions were 
observed in chromosome 1, 3 and 6 in 7, 6 and 8 karyotypes respectively. Many affected 
chromosomes were identified in samples treated with 10 mg, with interstitial deletions found 
in 3q3q4, q6, 4q1q5, 8q2, 12q4q5, 14q1, 16q2 and 18q1. The analysis of banded 
chromosomes is more labor-intensive than standard cytogenetic analysis (Hoffmann, 1996) 
but gives more detail. Although the number of the examined banded karyotypes was limited, 
interstitial deletions were determined in several banded chromosomes, suggesting that such 
bands may be found near a locus responsible for regulating leukotriene receptors. Therefore, 
treatment with Montelukast (a leukotriene receptor antagonist)  may   affect  such regions and 
lead to the absence of the mentioned bands. 
Literature relating to the pharmacologic effects and therapeutic uses of Montelukast is 
abundant, but data concerning mutagenic assays are lacking from animal models or humans. 
Asthma is known to be a complex polygenic disorder with marked gene-environment 
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interaction. Several genes related to bronchial hyper-responsiveness (BHR) and atopy have 
been identified. Postma et al. (1995) found that a gene governing  BHR is located near a 
major locus that regulates serum immunoglobulin (IgE) levels on chromosome 5q. Sandford 
et al. (1996) found that a cluster of cytokine gene on chromosome 5q31q33 are linked to 
atopy and BHR. Furthermore, genome scans have identified other regions of interest on 
chromosomes 2q, 4, 5p, 6, 7, 11p, 13, 16, 17, 19q and 21q (Abramson & Harrap 1998). The 
present results indicate genotoxic potential of the drug in somatic cells of mouse in vivo. 
Further investigations should be conducted to substantiate the mutagenic effect of  
Montelukast  on human cells. 
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  الملخص العربى
 
راسات د: على الفئران البيضاء) نت ليوكاستمو(التأثير الوراثى الخلوى لعقـار الربـو والحساسـية الجديد 
  كروموسومية
 
   سحر عبد الرازق مسلم– إيمان عبد المنعم درويش –كريمة محمد سويفى 
   القاهرة-كلية البنات لألداب والعلوم والتربية جامعة عين شمس 
 
مونت ليوكاست صوديوم المضاد لمستقبالت الليكوترين يوصف لتهدئة أعراض أزمات  الربو وكذلك لعالج  العقار
منع المعاناة من األعراض التى تظهر خالل النهار وأثناء الليل ، عالج حاالت : حاالت الربو المزمنة والتى تشمل 
وهو . لتى تظهر عقب التمرينات الرياضية البسيطة الحساسية من تناول األسبرين ، فانه يمنع أعراض انقباض الشعب ا
ونظرا ألهمية هذا الدواء ولعدم الشكوى من ظهور . دواء مفيد لتقليل الحاجة للكورتيزون في أزمات الربو المستمرة 
أية أعراض جانبية خطيرة قد تظهر أثناء االستعمال ،يهدف  البحث الحالى الى إلقاء الضوء على الضرر الذى قد 
 ٥(وقد استخدم مونت ليوكاست بجرعتين .  ثه عقار مونت ليوكاست على المحتوى الوراثى الخلوى لخاليا الفئران يحد
 أيام متتالية ، وتم تحضير كروموسومات المرحلـة االستوائية من خاليا نخاع العظم بعد األيام ٨لمدة ) يوم/ مجم١٠، 
ومية في خاليا الحيوانات المعالجة وذلك في كل أزمنة التجربة   ارتفعت نسبة التغيرات الكروموس٨ ،  ، ٣ ، ٢ ، ١
 ساعة وبلغت أقصاها بعد اليوم الثامن وبمقارنة تأثير الجرعتين ٢٤وبالجرعتين المستخدمتين، بدأ االرتفاع بعد 
 قد  و. المستخدمتين تبين أن النتائج تناسبت طرديا مع تركيز الجرعة من جهة ومع زمن التجربة من جهة أخرى 
أمكن من خالل فحص وتحليل الهيئة .ات العددية فى كل العينات وانخفضت بعد اليوم الثامن ارتفعت نسبة التغير
 ، ٢ ، ١الكروموسومية المجهزة بتقنية الحزم  مالحظة انتقاصـات بينية فى حزم معينة لكل من الكروموسومات أرقام 
ح للعقار المستخدم على مما سبق يتضح التأثير المطفر الواض . ١٨ و ١٦ ، ١٤ ، ١٢ ، ٨ ، ٦ ، ٤ ، ٣
  .كروموسومات الخاليا الجسدية للفأر األبيض  لذلك يجب الحذر عند استخدامه على المستوى البشرى
 
